Minerva Neurosciences, Inc. (NERV) Current Ratio
- Current ratio · latest quarter: Value 20.14×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 20.14× | Current assets / current liabilities. $79.73M ÷ $3.96M ≈ 20.14× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 79.73M USD | Assets, Current |
| Current obligations | 3.96M USD | Liabilities, Current |
| Cash and equivalents | 24.65M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 50.62M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 1.45M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $79.73M | $3.96M | $24.65M | $50.62M | (m) | (m) | $1.45M | (m) | 20.14× |
| 2026-03-31 | $79.11M | $4.48M | $32.66M | $45.41M | (m) | (m) | $2.12M | (m) | 17.65× |
| 2025-12-31 | $83.10M | $2.29M | $82.30M | (m) | (m) | (m) | $639.71K | (m) | 36.28× |
| 2025-09-30 | $13.02M | $2.67M | $12.29M | (m) | (m) | (m) | $944.49K | (m) | 4.87× |
| 2025-06-30 | $15.55M | $2.53M | $15.25M | (m) | (m) | (m) | $896.80K | (m) | 6.15× |
| 2025-03-31 | $17.92M | $1.95M | $17.29M | (m) | (m) | (m) | $639.95K | (m) | 9.21× |
| 2024-12-31 | $22.27M | $2.84M | $21.36M | (m) | (m) | (m) | $1.61M | (m) | 7.85× |
| 2024-09-30 | $27.94M | $4.48M | $26.53M | (m) | (m) | (m) | $553.19K | (m) | 6.23× |
| 2024-06-30 | $31.41M | $4.20M | $30.88M | (m) | (m) | (m) | $828.35K | (m) | 7.47× |
| 2024-03-31 | $35.62M | $2.83M | $34.82M | (m) | (m) | (m) | $1.44M | (m) | 12.58× |
| 2023-12-31 | $42.00M | $3.34M | $40.91M | (m) | (m) | (m) | $1.81M | (m) | 12.57× |
| 2023-09-30 | $48.23M | $3.35M | $46.90M | (m) | (m) | (m) | $1.40M | (m) | 14.40× |
| 2023-06-30 | $52.23M | $1.91M | $51.80M | (m) | (m) | (m) | $298.25K | (m) | 27.37× |
| 2023-03-31 | $36.67M | $2.50M | $35.98M | (m) | (m) | (m) | $961.00K | (m) | 14.66× |
| 2022-12-31 | $40.16M | $1.38M | $36.09M | (m) | (m) | (m) | $969.67K | (m) | 29.15× |
| 2022-09-30 | $44.84M | $2.20M | $40.22M | (m) | (m) | (m) | $532.89K | (m) | 20.41× |
| 2022-06-30 | $50.04M | $3.41M | $49.75M | (m) | (m) | (m) | $1.52M | (m) | 14.68× |
| 2022-03-31 | $55.70M | $3.25M | $54.95M | (m) | (m) | (m) | $1.59M | (m) | 17.15× |
| 2021-12-31 | $62.20M | $2.82M | $60.76M | (m) | (m) | (m) | $1.85M | (m) | 22.07× |
| 2021-09-30 | $67.44M | $3.08M | $65.59M | (m) | (m) | (m) | $1.20M | (m) | 21.88× |
| 2021-06-30 | $75.23M | $4.44M | $74.21M | (m) | (m) | (m) | $1.59M | (m) | 16.93× |
| 2021-03-31 | $81.69M | $3.36M | $80.14M | (m) | (m) | (m) | $1.13M | (m) | 24.32× |
| 2020-12-31 | $27.44M | $3.16M | $25.36M | (m) | (m) | (m) | $995.61K | (m) | 8.68× |
| 2020-09-30 | $34.99M | $5.39M | $32.52M | (m) | (m) | (m) | $701.59K | (m) | 6.49× |
| 2020-06-30 | $35.89M | $7.40M | $32.25M | $3.00M | (m) | (m) | $3.14M | (m) | 4.85× |
| 2020-03-31 | $38.47M | $7.12M | $30.04M | $7.48M | (m) | (m) | $3.00M | (m) | 5.40× |
| 2019-12-31 | $47.14M | $6.63M | $21.41M | $24.44M | (m) | (m) | $2.32M | (m) | 7.11× |
| 2019-09-30 | $61.41M | $9.90M | $37.91M | $22.03M | (m) | (m) | $5.33M | (m) | 6.21× |
| 2019-06-30 | $70.85M | $7.59M | $27.84M | $41.45M | (m) | (m) | $2.94M | (m) | 9.34× |
| 2019-03-31 | $80.32M | $6.90M | $30.61M | $48.56M | (m) | (m) | $3.03M | (m) | 11.64× |
| 2018-12-31 | $90.02M | $3.61M | $50.23M | $37.76M | (m) | (m) | $1.80M | (m) | 24.94× |
| 2018-09-30 | $101.40M | $3.87M | $87.30M | $10.31M | (m) | (m) | $874.75K | (m) | 26.20× |
| 2018-06-30 | $111.82M | $5.02M | $68.69M | $39.80M | (m) | (m) | $1.31M | (m) | 22.28× |
| 2018-03-31 | $125.34M | $7.91M | $45.13M | $75.87M | (m) | (m) | $2.82M | (m) | 15.84× |
| 2017-12-31 | $129.54M | $6.84M | $26.05M | $102.11M | (m) | (m) | $1.44M | (m) | 18.94× |
| 2017-09-30 | $134.08M | $8.72M | $36.25M | $96.68M | (m) | (m) | $1.50M | (m) | 15.38× |
| 2017-06-30 | $78.07M | $14.59M | $50.19M | $27.38M | (m) | (m) | $1.43M | (m) | 5.35× |
| 2017-03-31 | $86.23M | $12.99M | $68.89M | $16.46M | (m) | (m) | $3.28M | (m) | 6.64× |
| 2016-12-31 | $83.86M | $9.69M | $82.98M | (m) | (m) | (m) | $1.47M | (m) | 8.66× |
| 2016-09-30 | $92.64M | $10.10M | $91.85M | (m) | (m) | (m) | $833.23K | (m) | 9.17× |
| 2016-06-30 | $97.42M | $6.24M | $88.67M | $8.39M | (m) | (m) | $876.51K | (m) | 15.62× |
| 2016-03-31 | $45.34M | $6.97M | $34.82M | $9.82M | (m) | (m) | $1.22M | (m) | 6.51× |
| 2015-12-31 | $33.48M | $5.32M | $14.28M | $17.92M | (m) | (m) | $1.36M | (m) | 6.29× |
| 2015-09-30 | $38.81M | $3.21M | $16.84M | $20.65M | (m) | (m) | $734.80K | (m) | 12.09× |
| 2015-06-30 | $35.78M | $3.81M | $21.74M | $13.65M | (m) | (m) | $564.29K | (m) | 9.38× |
| 2015-03-31 | $52.74M | $4.43M | $52.20M | (m) | (m) | (m) | $1.03M | $-158.26K | 11.92× |
| 2014-12-31 | $19.34M | $3.51M | $18.55M | (m) | (m) | (m) | $641.81K | (m) | 5.51× |
| 2014-09-30 | $24.22M | $3.18M | $23.64M | (m) | (m) | (m) | $942.23K | (m) | 7.62× |
| 2014-06-30 | $513.22K | $10.05M | $480.01K | (m) | (m) | (m) | $4.32M | (m) | 0.05× |
| 2013-12-31 | $1.82M | $1.41M | $1.82M | (m) | (m) | (m) | $522.98K | (m) | 1.29× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |